A Phase 2 Study of BNC210 for the Acute Treatment of Social Anxiety Disorder
Status:
Recruiting
Trial end date:
2022-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the effects of an acute dose of BNC210 compared to
placebo on reducing anxiety provoked by a speaking challenge and measured using the
Subjective Units of Distress Scale (SUDS) in patients with Social Anxiety Disorder (SAD).